The FLT-3 (AML) Mutation Panel / EDTA Blood is a specialized molecular test used to detect FLT-3 gene mutations associated with acute myeloid leukemia (AML). These mutations help guide prognosis, treatment planning, and eligibility for targeted therapies. Performed using advanced molecular techniques at Metropolis Healthcare, this test provides high-accuracy assessment of FLT-3 alterations. It is especially useful for newly diagnosed AML patients or those requiring treatment stratification.
Price:
Rs. 5,830.00
Sample Type: EDTA BLOOD
Fasting Not Requierd
Frequently Asked Questions (FAQ's):
What does the FLT-3 (AML) Mutation Panel include?
This panel at Metropolis Healthcare detects key FLT-3 gene mutations, including ITD and TKD variants associated with AML.
How does Metropolis Healthcare perform this mutation analysis?
Metropolis Healthcare uses advanced PCR-based and molecular sequencing methods to accurately identify FLT-3 mutations from EDTA blood.
Who should take this test?
Patients diagnosed with acute myeloid leukemia or suspected AML may benefit from this test at Metropolis Healthcare.
Why is FLT-3 testing important in AML?
Metropolis Healthcare performs this test to help determine prognosis and guide the use of targeted FLT-3 inhibitor therapies.
What sample is required for the test?
An EDTA blood sample is used by Metropolis Healthcare to analyze FLT-3 mutations.
How long does it take to receive results?
Metropolis Healthcare typically provides results within a clinically relevant turnaround time due to the urgent nature of AML diagnosis.
Can this test help guide treatment decisions?
Yes, doctors rely on Metropolis Healthcare’s FLT-3 mutation results to tailor chemotherapy and targeted therapy plans.
Is this test useful for monitoring disease progression?
Yes, Metropolis Healthcare may recommend repeat testing in certain cases to track mutation status during treatment.